Ypsomed Holding AG (YPHDF)
OTCMKTS
· Delayed Price · Currency is USD
417.98
0.00 (0.00%)
At close: Apr 29, 2025
Ypsomed Holding AG Revenue
Ypsomed Holding AG had revenue of 324.01M CHF in the half year ending September 30, 2024, with 32.66% growth. This brings the company's revenue in the last twelve months to 617.07M, up 21.33% year-over-year. In the fiscal year ending March 31, 2024, Ypsomed Holding AG had annual revenue of 548.46M with 10.25% growth.
Revenue (ttm)
617.07M CHF
Revenue Growth
+21.33%
P/S Ratio
7.93
Revenue / Employee
268.76K CHF
Employees
2,296
Market Cap
5.79B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 548.46M | 51.00M | 10.25% |
| Mar 31, 2023 | 497.46M | 32.62M | 7.02% |
| Mar 31, 2022 | 464.84M | 61.19M | 15.16% |
| Mar 31, 2021 | 403.66M | 9.39M | 2.38% |
| Mar 31, 2020 | 394.26M | -59.50M | -13.11% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Ypsomed Holding AG News
- 5 months ago - Novo Nordisk (NVO) Partners with Ypsomed for Next-Gen Obesity Drug Delivery - GuruFocus
- 5 months ago - Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens - Seeking Alpha